<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074160</url>
  </required_header>
  <id_info>
    <org_study_id>OCSLIVER-01-PAS</org_study_id>
    <nct_id>NCT05074160</nct_id>
  </id_info>
  <brief_title>OCS Liver Perfusion (OLP) Post-Approval Registry</brief_title>
  <official_title>OCS Liver Perfusion (OLP) Post-Approval Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the OLP Registry is to collect more data on the post-transplant clinical&#xD;
      outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to&#xD;
      the approved indication and the OCS device performance in the real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OLP Registry is a multi-center, observational post-approval registry of adult primary liver&#xD;
      transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver&#xD;
      according to the approved indication and that match the eligibility criteria below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>1 year post-Liver transplant</time_frame>
    <description>1-year patient survival with the originally transplanted liver (patient and graft survival) post-Liver transplant.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>6 months post-Liver transplant</time_frame>
    <description>6-months liver graft survival post-Liver transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Long Term Patient Survival</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>K-M Patient survival at 1- and 2-years post-transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Long Term Graft Survival</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>K-M Graft survival at 6 months, 1- and 2-years post-transplant</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>OLP Registry primary analysis population</arm_group_label>
    <description>Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Liver</intervention_name>
    <description>Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.</description>
    <arm_group_label>OLP Registry primary analysis population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants in the OLP Registry will be all adult primary liver transplant&#xD;
        candidates on the waiting list for liver transplant at a U.S. liver transplant center and&#xD;
        who meet the eligibility criteria at the participating Registry centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult primary liver transplant recipients of DBD or DCD donor Livers perfused on OCS&#xD;
             Liver System&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Donor livers with accessory arterial blood supply requiring back table anastomosis,&#xD;
             major traumatic injury, or hematoma; or&#xD;
&#xD;
          -  Split donor liver; or&#xD;
&#xD;
          -  DCD donor liver with &gt;30 minutes of warm ischemic time (defined as from withdrawal of&#xD;
             life support until donor liver cold flush); or&#xD;
&#xD;
          -  DCD donors age &gt;55 years; or&#xD;
&#xD;
          -  DCD donor liver with macrosteatosis of &gt;15%&#xD;
&#xD;
          -  Living donors&#xD;
&#xD;
          -  Donors with positive serology for HIV, Hep B and C&#xD;
&#xD;
          -  Donors with macrosteatosis of â‰¥40%&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  Fulminant liver failure; or&#xD;
&#xD;
          -  Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant;&#xD;
             or&#xD;
&#xD;
          -  Chronic renal dialysis at time of transplant; or&#xD;
&#xD;
          -  Dependency on more than 1 inotropic agent to maintain hemodynamics; or&#xD;
&#xD;
          -  Ventilator dependent at time of transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly Jork</last_name>
    <phone>978-552-0974</phone>
    <email>kjork@transmedics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kausar Qidwai</last_name>
    <phone>978-552-0984</phone>
    <email>kqidwai@transmedics.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

